EUVIMEDEUVIMED entdecken
Leserbrief

High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma

Thilo Gambichler iD, Fahimeh Razeghpour, Emilia Sorescu, Markus Stücker, Nessr Abu Rached, Jürgen C Becker, Laura Susok

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae171 ↗

Kurz gefasst

Leserbrief in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Thilo Gambichler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, 5-Methylcytosine, Neoplasm Recurrence, Local. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxymethylation plays a significant role in cancer development and progression. We hypothesized that hydroxymethylation markers may have prognostic potential in AFX/PDS (atypical fibroxanthoma/pleomorphic dermal sarcoma) as also observed in other tumours. Moreover, we wanted to find out whether hydroxymethylation markers might aid differentiation between AFX and PDS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin Neoplasms5-MethylcytosineNeoplasm Recurrence, LocalHumansFemaleMaleAgedMiddle AgedHistiocytoma, Benign FibrousAged, 80 and overSarcoma

Substanzen

5-Methylcytosine5-hydroxymethylcytosine

Autor:innen und Institutionen

  • Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
  • Department of Dermatology, Christian Hospital Unna, Unna, Germany.
  • Department of Dermatology, Dortmund Hospital gGmbH and Faculty of Health, University of Witten-Herdecke, Dortmund, Germany.
  • Translational Skin Cancer Research, DKTK Partner Site Essen/Düsseldorf, West German Cancer Center, Dermatology, University Duisburg-Essen, Essen, Germany.
  • German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Thilo Gambichler

Zitieren

APA

Gambichler, T., Razeghpour, F., Sorescu, E., Stücker, M., Abu Rached, N., Becker, J. C., & Susok, L. (2024). High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae171

Vancouver

Gambichler T, Razeghpour F, Sorescu E, Stücker M, Abu Rached N, Becker JC, et al. High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae171

BibTeX
@article{Gambichler2024,
  author = {Gambichler, Thilo and Razeghpour, Fahimeh and Sorescu, Emilia and Stücker, Markus and Abu Rached, Nessr and Becker, Jürgen C and Susok, Laura},
  title = {High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae171}
}
Kostenlos starten →